Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase NA 1Phase 3 1Phase 2 1

Status

Completed 6Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 1Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Melanoma 8Lung Neoplasms 8Neoplasm Metastasis 6Colorectal Neoplasms 6Solid Tumours 5Neoplasms 5Breast Neoplasms 4Uveal Melanoma 3Thyroid Neoplasms 3Pancreatic Neoplasms 3Neurofibromatosis 1 3Colonic Neoplasms 3Thyroid Cancer, Papillary 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Adult Solid Neoplasm 2Thyroid Diseases 1Thymoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Optic Nerve Glioma 1Non-small Cell Lung Cancer Metastatic 1Neurofibrosarcoma 1Neurofibroma, Plexiform 1Neuroblastoma 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × AZD 6244 × Clear all
NCT01750281 2023-10-24

SELECT-2

AstraZeneca

Phase 2 Completed
212 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03745989 2023-07-27

MK-8353-014

Merck Sharp & Dohme LLC

Phase 1 Completed
30 enrolled 19 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01809210 2018-03-13

SELECT-3

AstraZeneca

Phase 1 Completed
55 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00970359 2017-04-12

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

Memorial Sloan Kettering Cancer Center

Phase NA Completed
24 enrolled 8 charts
Head & Neck

Neoplasm Metastasis, Thyroid Diseases, Thyroid Neoplasms

NCT01974752 2017-01-05

SUMIT

AstraZeneca

Phase 3 Completed
152 enrolled 14 charts
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT01605916 2016-10-21

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

AstraZeneca

Phase 1 Completed
33 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡